Skip to content
GLP-1/glucagon dual agonists

Mazdutide vs Survodutide

The table compares the compounds’ key data from their entry pages. Open each compound’s full entry for details. Educational content, not medical advice.

What it is
Mazdutide (IBI362)Obesity drug acting on GLP-1 and glucagon, approved in China in 2025; elsewhere still investigational.
SurvodutideExperimental obesity and diabetes medicine in late-stage trials that imitates glucagon and GLP-1.
Type
Mazdutide (IBI362)GLP-1 / glucagon dual agonist
SurvodutideGlucagon / GLP-1 dual agonist
Structure
Mazdutide (IBI362)Oxyntomodulin-based analog
SurvodutideLipidated 29-aa glucagon analog
Status
Mazdutide (IBI362)Approved in China (2025)
SurvodutidePhase 3
Route
Mazdutide (IBI362)SC, once weekly
SurvodutideSC, once weekly
Storage
Mazdutide (IBI362)2–8°C
Survodutide2–8°C

Mazdutide or survodutide: what is the difference?

Both copy the action of two hormones at once, GLP-1 and glucagon, and both are being developed to treat obesity. Their structures differ: according to its entry mazdutide is an oxyntomodulin-based analog, while survodutide is a lipidated glucagon analog of 29 amino acids. Mazdutide is a joint project of Innovent Biologics and Eli Lilly; survodutide is being studied not only for obesity but also for type 2 diabetes and MASH, metabolic-related fatty liver inflammation. The biggest difference is status: mazdutide was approved in China in 2025 for obesity and is investigational elsewhere, while survodutide is not yet approved and is being tested in late-stage, phase 3 human trials.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant